Journal
PEDIATRIC NEPHROLOGY
Volume 37, Issue 8, Pages 1845-1853Publisher
SPRINGER
DOI: 10.1007/s00467-021-05395-z
Keywords
Henoch-Schonlein purpura nephritis; IgA vasculitis; RAS inhibitors; Recurrence; Prognosis; Pediatrics
Categories
Ask authors/readers for more resources
Japanese childhood HSPN cases with moderate severity have good outcomes without the need for corticosteroids or immunosuppressants when prescribed RAS inhibitor treatment. Even in recurrent cases, abnormal proteinuria is transient, and prognosis is excellent.
Background Cases of Henoch-Schonlein purpura nephritis (HSPN) with moderate severity were demonstrated to achieve good prognosis after treatment with renin-angiotensin system (RAS) inhibitors. However, some patients required additional treatment for recurrence after remission. This study aimed to clarify the effect of RAS inhibitors in HSPN cases with moderate severity, including the proportion of cases with recurrence and their response to additional treatment. Methods Among 126 patients diagnosed with HSPN between 1996 and 2019, 71 patients with clinicopathologically diagnosed HSPN of moderate severity, defined as ISKDC grade II-IIIa and serum albumin >= 2.5 g/dL, were investigated. Results Proteinuria became negative after RAS inhibitor treatment alone in all 71 cases. However, 16 (22.5%) had recurrence. Eleven recurrent cases achieved negative proteinuria again following additional treatment. At the last follow-up (median 46.5 months; IQR, 23.2-98.2), 5 patients had persistent mild proteinuria; no patients had estimated glomerular filtration rate < 90 mL/min/1.73 m(2). The pathological findings in all recurrent cases were ISKDC grade Ma. The 16 recurrent cases had significantly higher proportions of glomeruli with global/segmental sclerosis (25.0 vs. 0%, P < 0.001) and tubular atrophy/interstitial fibrosis (37.5 vs. 12.7%, P =0.0 24) than 55 cases without recurrence. Conclusions Japanese childhood HSPN cases with moderate severity had good outcomes without need for corticosteroids or immunosuppressants, when prescribed RAS inhibitor treatment. Even in recurrent cases, abnormal proteinuria was transient, and prognosis was excellent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available